Y-MABS THERAPEUTICS INC. - COMMON STOCK

Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities

10 Jan 2025 08:26:05 By Nasdaq GlobeNewswire

Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

10 Jan 2025 06:35:00 By Nasdaq GlobeNewswire

Y-mAbs Provides Strategic Business Update and 2025 Priorities

10 Jan 2025 06:05:00 By Nasdaq GlobeNewswire

Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference

23 Dec 2024 06:30:00 By Nasdaq GlobeNewswire

Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting

07 Dec 2024 11:00:00 By Nasdaq GlobeNewswire

Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference

27 Nov 2024 06:35:00 By Nasdaq GlobeNewswire

Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments

08 Nov 2024 05:35:00 By Nasdaq GlobeNewswire

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan

04 Nov 2024 06:35:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast

25 Oct 2024 06:05:00 By Nasdaq GlobeNewswire

Y-mAbs to Participate in Upcoming Investor Conferences in October

01 Oct 2024 06:05:00 By Nasdaq GlobeNewswire

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research

06 Sep 2024 06:30:00 By Nasdaq GlobeNewswire

Y-mAbs to Participate in Upcoming Investor Conferences in September

03 Sep 2024 07:32:32 By Nasdaq GlobeNewswire

Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

12 Aug 2024 05:30:00 By Nasdaq GlobeNewswire

Y-mAbs to Participate in Upcoming Investor Conferences in August

07 Aug 2024 06:05:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast

05 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

01 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting

07 Jun 2024 06:05:00 By Nasdaq GlobeNewswire

Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

05 Jun 2024 06:05:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting

01 Jun 2024 07:15:00 By Nasdaq GlobeNewswire

Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting

01 Jun 2024 07:05:00 By Nasdaq GlobeNewswire